BioBiz Buzz

12. Revolution technology set to transform breast cancer diagnosis and treatment.

https://biobizbuzz.com/ Season 1 Episode 12

Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according to the World Health Organization. The Global Breast Cancer Initiative (GBCI), is working to reduce breast cancer deaths by 2.5% each year, preventing 2.5 million deaths by 2040. Early accurate diagnosis and effective treatment are key to achieving this.

In this episode of Biobiz Buzz, your host Shani Alexander is joined by two guests from Resitu Medical, Åsa Runnäs, CEO, and Elisabeth Liljensten, Chief Clinical Officer to discuss the company’s game-changing technology that has the potential to not only change the way breast cancer is diagnosed but also treated.

Runnäs and Liljensten reveals that their vacuum assisted, minimally invasive, ultrasound guided device uses diathermy to remove entire breast lesions, not just fragments, for histopathological examination. Unlike current methods that excise small tissue samples which may require follow up surgery if cancer is confirmed, the Resitu device can remove the entire lesion. The device works in outpatient settings, making it available to millions of women in countries where surgical theatres, anaesthesiologists etc. are lacking and it is unclear whether they will be diagnosed or treated.

This disruptive technology has the potential to eliminate the need for open surgery, as it offers a simpler, safer, faster and less invasive solution to remove the lesion and save the lives of millions of people around the world.

Feedback

Subscribe (Get notified when new episodes are available. NO marketing!)

Disclaimer

LinkedIn